We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Management of adjuvant S-1 therapy after curative resection of gastric cancer: dose reduction and treatment schedule modification.
- Authors
Iwasa, Satoru; Yamada, Yasuhide; Fukagawa, Takeo; Nakajima, Takako Eguchi; Kato, Ken; Hamaguchi, Tetsuya; Morita, Shinji; Saka, Makoto; Katai, Hitoshi; Shimada, Yasuhiro
- Abstract
Background: The aim of this study was to determine the optimal management of adjuvant S-1 therapy for stage II or III gastric cancer, encompassing the details of dose reduction and treatment schedule modification. Methods: We retrospectively examined 97 patients with stage II or III gastric cancer who received S-1 chemotherapy following gastrectomy between January 2003 and December 2007. S-1 (80 mg/m per day) was orally administered twice daily for 4 weeks, followed by a 2-week rest. As a rule, treatment was continued for 1 year after gastrectomy. Dose reduction or treatment schedule modification was performed according to toxicity profiles. Results: Among the 97 patients, 57 (59%) underwent dose reduction at least once and 39 (40%) received treatment schedule modification. Of the 57 patients who required dose reduction, 45 (79%) underwent reduction within 3 months of the beginning of treatment. The most common reasons for dose reduction were anorexia (47%), followed by diarrhea (32%), leukopenia (24%), and rash (16%), with the reasons overlapping. Although the difference in the requirement for dose reduction was not significant, patients with a low creatinine clearance level or those who underwent total gastrectomy had a greater tendency to require dose reduction. The duration of the S-1 treatment period was at least 3 months in 88% of the patients, at least 6 months in 82%, and the planned 1-year period in 73% of the patients. Conclusions: In most patients, the planned 1-year adjuvant S-1 therapy for stage II or III gastric cancer could be completed by modifying the dose reduction and treatment schedule.
- Subjects
CANCER treatment; STOMACH cancer; IMMUNOLOGICAL adjuvants; STOMACH surgery; DRUG therapy
- Publication
Gastric Cancer, 2011, Vol 14, Issue 1, p28
- ISSN
1436-3291
- Publication type
Article
- DOI
10.1007/s10120-011-0003-y